University of Cambridge > > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > Epigenomic pathways in cancer and in cancer immunotherapy

Epigenomic pathways in cancer and in cancer immunotherapy

Add to your list(s) Download to your calendar using vCal

  • UserShelley Berger, Epigenetics Institute, Departments of Cell and Developmental Biology, Genetics, Biology, University of Pennsylvania
  • ClockThursday 23 February 2017, 16:00-17:00
  • HouseCRUK CI Lecture Theatre.

If you have a question about this talk, please contact Kate Davenport.


Cancer is both a genomic and epigenomic disease, given that numerous chromatin pathways have been implicated as drivers in cancer. Our study of p53 in human cancer has revealed an important role of epigenomic regulation in several cancers involving gain-of-function mutant p53, and in teratocarcinoma cancer, which involves wild type p53. In the former case, mutant p53 drives expression of gene-activating histone modifiers, and in the latter case, wild type p53 is modified by gene-repressive modifications – in both cases permitting the expression of growth accelerating genes and pathways. Immunotherapy is a new and exciting area of clinical cancer treatment. While some individuals respond, others show resistance. We are investigating epigenetic pathways that may inhibit effective cancer immunotherapy, and other epigenetic pathways that may provide exceptionally potent response.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity